We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 728

Angiomax Patents Limited To Example
  • Foley & Lardner LLP
  • USA
  • April 18 2017

In The Medicines Co. v. Mylan, Inc., the Federal Circuit construed composition claims of two Angiomax patents as requiring the recited “batches” to


PTAB Not Bound By Prior Court Decisions Upholding Exelon Patents
  • Foley & Lardner LLP
  • USA
  • April 11 2017

In Novartis v. Noven Pharmaceuticals, Inc., the Federal Circuit affirmed the USPTO Patent Trial and Appeal Board (PTAB) decisions invalidating


Will The Avastin Biosimilar Patent Dance Go On?
  • Foley & Lardner LLP
  • USA
  • March 7 2017

Judge Sleet of the U.S. District Court for the District of Delaware has dismissed Genentech’s complaint against Amgen for allegedly failing to comply


One is Not Enough - Infringement Liability under 271(f)(1)
  • Foley & Lardner LLP
  • USA
  • March 6 2017

In Life Technologies Corp. v. Promega Corp., Slip Op. 14-1538 (Feb. 22, 2017), the U.S. Supreme Court held that the supply of a single component of a


PTAB Puts Method Of Treatment Patents Under The 101 Knife
  • Foley & Lardner LLP
  • USA
  • February 28 2017

While the Supreme Court decisions in Myriad and Mayo have been applied to diagnostic-type claims, method of treatment patents were thought to be safe


Expansion of the Patent-Ineligibility Doctrine: Are Method of Treatment Claims Patent-Eligible?
  • Foley & Lardner LLP
  • USA
  • February 27 2017

While Supreme Court decisions in Myriad and Mayo (and the subsequent Federal Circuit decision in Sequenom) pulled diagnostic claims under the gambit


Supreme Court Reigns in International Supplier Liability under U.S. Patent Law
  • Foley & Lardner LLP
  • USA
  • February 23 2017

On February 22, 2017, the Supreme Court handed down a unanimous opinion in Life Technologies. Corp. v. Promega Corp. (Roberts, C.J., recused


Will You, Won't You Join The Biosimilar Patent Dance?
  • Foley & Lardner LLP
  • USA
  • February 21 2017

In the latest dispute surrounding the “patent dance” provisions of the Biologics Price Competition and Innovation Act (BPCIA), Genentech, Inc. has


Federal Circuit knocks out patents after CBM challenge
  • Foley & Lardner LLP
  • USA
  • February 20 2017

Apple successfully invalidated three patents for failure to recite patent eligible subject matter. Apple, Inc. v. Ameranth, Inc., 2015-1792


Federal Circuit knocks out patents after CBM challenge
  • Foley & Lardner LLP
  • USA
  • February 20 2017

Apple successfully invalidated three patents for failure to recite patent eligible subject matter. Apple, Inc. v. Ameranth, Inc., 2015-1792